Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
Rohith Palli(University of Rochester), Juilee Thakar, Glenda Gray(South African Medical Research Council), Susan Buchbinder(University of California, San Francisco), Gavin Churchyard(University of the Witwatersrand), Paul Goepfert(University of Maryland, Baltimore), Georgia D. Tomaras(National Institutes of Health), Harriet L. Robinson(GeoVax (United States)), James J. Kobie(University of Alabama at Birmingham), Holly Janes(Fred Hutch Cancer Center), Fatima Laher(University of the Witwatersrand), Michael S. Piepenbrink(University of Alabama at Birmingham), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Kelly E. Seaton(International Vaccine Institute), Michael C. Keefer(University of Rochester Medical Center), Yunda Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 10
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the <i>CKR5</i> Structural Gene
|Science|1996|2.5k
Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa
|The Lancet|2004|1.3k
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
|The Lancet|2008|708
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661